BRCA1 and ovarian carcinoma: Interestingly, the ARIEL2 study included patients with germline BRCA1/2-wild type platinum sensitive recurrent ovarian cancers, but utilized a next generation sequencing loss of heterozygosity (LOH) assay that as a biomarker for HR deficiency in BRCA1/2-wild type platinum sensitive ovarian cancers.